Zavain Dar, a founder and partner at Dimension Capital, invests stage-agnostically (from pre-seed to public) at. See sector focus and contact routes.
Zavain Dar, a founder and partner at Dimension Capital, invests stage-agnostically (from pre-seed to public) at the intersection of life sciences and technology, with a distinctive thesis on AI-driven drug discovery and the convergence of biology and computer science. His firm’s check sizes range from $1 million to over $30 million, supporting sectors including AI/ML in biotech, computational biology, lab automation, and biopharma infrastructure. Notable portfolio companies include Chai Discovery (an AI foundational model for drug discovery with a $1.3B valuation), Enveda Biosciences (AI + natural compounds), and Recursion Pharmaceuticals (NASDAQ: RXRX). Dar claims Dimension is the first VC firm dedicated solely to bridging biology and computer science.
Every field above is read from the StartupFundraising investor directory — disclosed location, recorded investments and stated focus — and re-checked as filings arrive. Founders pair it with investors in New York when building a target list.
Investors like Zavain Dar · Full investor directory · Investor access · Company funding database